I've heard from VPs that inside the Co they are disappointed that their profit/revenue hasn't yet hit their own projections. It's been a tough field. Nevro came along just prior and took a bunch of business. But as I alluded to before, shorting that other company may prove to be a serious gainer.
Boston Sci's new system out shortly (June-ish).
But NVTR still gaining traction.
I'm staying nimble with some Short term trading shares, but always holding at least 1k core shares for the long term gains.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.